Omalizumab use during pregnancy for CIU: a tertiary care experience.
Journal Article
The treatment of antihistamine and steroid resistant Chronic Idiopathic Urticaria (CIU) during pregnancy poses a challenge due to teratogenicity of immunosuppressants. Omalizumab is a recently FDA approved therapy for CIU and is classified as pregnancy category B. We present an initial series of subjects treated at a tertiary care center for antihistamine and steroid resistant CIU with omalizumab who became pregnant during therapy.
Full Text
Duke Authors
Cited Authors
- Cuervo-Pardo, L; Barcena-Blanch, M; Radojicic, C
Published Date
- July 2016
Published In
Volume / Issue
- 48 / 4
Start / End Page
- 145 - 146
PubMed ID
- 27425170
Pubmed Central ID
- 27425170
International Standard Serial Number (ISSN)
- 1764-1489
Language
- eng
Conference Location
- Italy